Embryonic stem cells and induced pluripotent stem cells are more promising to achieve myocardial regeneration (generation of new cardiomyocytes), compared to adult stem cells. However, these pluripotent cells remain associated with critical issues to initiate clinical application, including mass production of high-quality cells and regulation of cardiomyogenic differentiation (i.e. avoidance of tumour formation). In addition, insufficient maturation and inappropriate integration of stem cell-derived cardiomyocytes as well as suboptimal cell-delivery method into the heart have to be overcome. With firm determination to progress this approach toward clinical application, we currently conduct basics/translational research of these cells.

Immunity and inflammation play a vital role in development of and recovery from heart failure. Suzuki’s group has investigated the role of high-mobility group protein 1(HMGB-1), toll like receptors (TLRs) as well as cardiac alternatively-activated (M2) macrophages in heart failure. In addition to elucidating their basic molecular/cellular biological aspects, we challenge to apply these data for development of innovative therapies of heart failure and other diseases including post-operative adhesions.

Adult stem/progenitor cells are able to improve cardiac performance and structure by repairing the damaged myocardium primarily through secretion of reparative factors (paracrine effects). Suzuki’s 20-year research suggested that allogeneic mesenchymal stromal cells are the most promising cell type for this approach to be a clinically successful at the moment. His research has also identified the issues associated with the current cell-delivery methods (i.e. intramyocardial and intracoronary injection), including poor donor cell engraftment and risks of complications such as arrhythmia occurrence and coronary embolism.